CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

By Petrioli Roberto   Licchetta Antonella   Roviello Giandomenico   Pascucci Alessandra   Francini Edoardo   Bargagli Gianluca   Conca Raffaele   Miano Salvatora Tindara   Marzocca Giuseppe   Francini Guido    

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite

Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy

By          

Oncology Letters, Vol. 4, Iss. 5, 2012-01 ,pp. : 905-909

Spandidos Publications

Access to resources Recommend Favorite

Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

By Huang Zhao-Hui   Hua Dong   Du Xiang  

Cancer Chemotherapy and Pharmacology, Vol. 64, Iss. 5, 2009-10 ,pp. : 1001-1007

Springer Publishing Company

Access to resources Recommend Favorite

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?

By Suh Kwang   Kim Joo   Kim Do   Kim Young   Lee Chulho   Choi Sungho  

Annals of Surgical Oncology, Vol. 13, Iss. 11, 2006-11 ,pp. : 1379-1385

Springer Publishing Company

Access to resources Recommend Favorite